AUTH/2981/9/17: Member of the public v ViiV Healthcare — iPad use on a train (No breach)

📅 2017 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/2981/9/17
ComplainantMember of the public
CompanyViiV Healthcare
ProductTriumeq (dolutegravir/abacavir/lamivudine)
IssuePromotional material visible on an iPad on a train (public setting)
Applicable Code year2016
Clauses considered2, 9.1, 15.2, 26.1
Panel decisionNo breach of the Code
Key reasoningNo representative as defined by the Code was involved; material not directed at the public; difference between proactive public promotion vs someone reading over a shoulder
Complaint received26 September 2017
Case completed23 November 2017
AppealNo appeal

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A member of the public complained that a “representative” used an iPad on a train in a way that made Triumeq sales strategy and clinical information visible to other passengers.
  • The complainant worried an HIV patient could use the information to challenge their regimen with a nurse/doctor without understanding the overall treatment plan.
  • ViiV stated the individual was not a representative under the Code, but a third-party service supplier employee doing technical checks on iPad promotional materials.
  • The third-party employee said the material was open for about 10 minutes and he swiped through ~20 screens to test interactive functionality; he did not engage with other passengers.
  • ViiV said the train area was not overcrowded and there was an empty seat between the employee and the next passenger.
⚖️

Outcome

  • No breach of the Code was found.
  • No breach of Clause 15.2 (no representative as defined by the Code was involved).
  • No breach of Clause 26.1 (on balance, the circumstances did not amount to promotion of a prescription only medicine to the public).
  • No breach of Clause 9.1 (no failure to maintain high standards).
  • No breach of Clause 2 (circumstances did not bring discredit upon, or reduce confidence in, the pharmaceutical industry).
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training